Investigating Tizanidine's effects on arm movement in stroke patients
Effect of Neural Constraints on Movement in Stroke
This study is testing if the medication Tizanidine can help stroke patients improve their arm movements.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Northwestern University Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06666673 on ClinicalTrials.gov |
What this trial studies
This study examines how Tizanidine, a medication approved by the FDA, influences voluntary arm movements in individuals who have experienced a stroke. It employs a two-arm, cross-over, double-blinded, randomized controlled design involving 64 participants. Each participant will undergo brain MRI and complete a series of arm and hand experiments to assess motor control and brain activity before and after taking either Tizanidine or a placebo. The goal is to better understand the neural mechanisms behind movement impairments post-stroke to enhance rehabilitation strategies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 who have experienced a unilateral ischemic stroke at least six months prior and have significant motor impairment in one arm.
Not a fit: Patients with motor or sensory impairments in the unaffected limb or those with other neurological disorders affecting arm function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved rehabilitation techniques for stroke patients, enhancing their ability to regain movement in their affected limbs.
How similar studies have performed: Other studies have shown promise in using pharmacological interventions to enhance rehabilitation outcomes in stroke patients, suggesting this approach may yield beneficial results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment * Age between 18-80 * Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 15-45/66, Chedoke McMaster Stroke Assessment Hand section \<=4) * Ability to communicate, understand, and provide informed consent * Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension * MRI compatible * Intact skin on the hemiparetic arm * Ability to sit for three hours. Exclusion Criteria: * Motor or sensory impairment in the non-affected limb (FMA\<66, filament \>3.6) * Any brainstem and/or cerebellar lesion * untreated cardiovascular disease * History of neurologic disorder other than stroke that affects the arms * Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale * Current use of a pacemaker * History of seizure * Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol/alcohol injections \<12 months before participation * Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes * Current participation in any experimental rehabilitation or drug studies * Individuals with any known contraindications to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity * pregnant women or women who are nursing. Additionally, each participant will be asked to provide a list of their current medications and a medical screening questionnaire will be sent to their primary physician. Each participant's list of medications will be reviewed for possible interactions with the study drugs and, at the study physician's advice, will be excluded from the study or asked to withhold medications when applicable. A full list of potential drug interactions can be seen in "Medication Interactions", but concisely includes the following: medications with dopaminergic, serotonergic, or noradrenergic actions; central nervous system (CNS) depressants; antihypertensive/ antiarrhythmic agents; and hormonal medications/contraceptives.
Where this trial is running
Chicago, Illinois
- Northwestern University, Dept. of PTHMS 645 N Michigan Ave, Suite 1100 — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Julius Dewald, DPT, PhD — Northwestern University
- Study coordinator: Riegele Arceo
- Email: riegele.arceo@northwestern.edu
- Phone: 3129080847
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.